Vanguard Personalized Indexing Management LLC Reduces Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Vanguard Personalized Indexing Management LLC cut its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,802 shares of the medical instruments supplier’s stock after selling 114 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in West Pharmaceutical Services were worth $3,856,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of WST. Vanguard Group Inc. grew its position in West Pharmaceutical Services by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after purchasing an additional 104,740 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of West Pharmaceutical Services by 23.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock valued at $690,530,000 after buying an additional 369,792 shares during the last quarter. TD Asset Management Inc increased its position in shares of West Pharmaceutical Services by 38.4% in the 4th quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock valued at $232,244,000 after acquiring an additional 183,153 shares during the period. Findlay Park Partners LLP lifted its position in West Pharmaceutical Services by 30.6% during the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after acquiring an additional 139,800 shares during the period. Finally, ProShare Advisors LLC grew its stake in West Pharmaceutical Services by 13.9% during the 1st quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock valued at $198,117,000 after purchasing an additional 61,247 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Insiders Place Their Bets

In other news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Trading Up 0.6 %

Shares of NYSE:WST opened at $310.92 on Friday. The business has a 50-day moving average price of $304.11 and a 200-day moving average price of $337.96. The stock has a market cap of $22.55 billion, a price-to-earnings ratio of 41.02, a PEG ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same period last year, the company earned $2.11 earnings per share. The firm’s revenue was down 6.9% on a year-over-year basis. Equities analysts predict that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.